Modulight

0,9

EUR

−3,23 %

Företagskund

MODU

First North Finland

Medicinsk Utrustning & Service

Hälsovård

2 689 investerare följer bolaget.

−3,23%

−6,25%

−22,41%

−28,57%

−23,34%

−17,58%

−92,07%

-

−91,77%

Modulight är verksamt inom teknikbranschen. Bolaget designar, marknadsför och producerar biomedicinska laserprodukter som används inom onkologi, genetik och oftalmologi. Kunderna består primärt av sjukhus och företagskunder verksamma inom medicinteknik. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Störst verksamhet återfinns inom US.

Börsvärde

38,36 mn EUR

Omsatt (värde)

10,17 tn EUR

P/E (just.) (24e)

−4,98

EV/EBIT (adj.) (24e)

−3,37

EV/S (24e)

7,1

Direktavkastnings- % (24e)

-

Coverage

Rekommendation

Minska

Riktkurs

0.90 EUR

Uppdaterad

2024-10-22

Latest research

Latest analysis report

Released: 2024-10-22

Latest extensive report

Released: 2023-03-21

Risk

Business risk

Valuation risk

Låg

Hög

VisarAlla typer av innehåll

Analytikerkommentarför 6 timmar sedan av

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Drug development investment: Value creation through M&As and licensing agreements

Artikeli går av

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatoriskt pressmeddelandei går

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto

Ger dig möjlighet att följa bolag och beställa notifikationer

Tillgång till analytikerkommentarer och rekommendationer

Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg

Skapa användarkonto

Regulatoriskt pressmeddelandei går

Modulight Corporation's Shareholders’ Nomination Committee Composition

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video2024-12-16 11:00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulation of drug development

Analytikerkommentar2024-12-03 10:21 av

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analytikerkommentar2024-11-08 11:52 av

Pay-Per-Treatment model brings Modulight order intake

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The news adds further visibility to the progress of the revenue and PPT model in the coming years

Regulatoriskt pressmeddelande2024-11-08 08:25

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Aktieanalys2024-10-22 06:51 av

Modulight Q3'24: No clear signs of growth yet

Modulight's Q3 report showed no clear signs of a return to growth and revenue landed below expectations. Earnings and cash flow were roughly in line with our forecasts due to lower-than-expected costs.

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Analytikerkommentar2024-10-18 12:41 av

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight's revenue was well below our expectations, but profit and cash flow were close to our forecasts. Revenue was negatively impacted by the transition to the PPT (pay-per-treatment) model and delays in prototype deliveries.

Regulatoriskt pressmeddelande2024-10-18 10:00

Modulight: Cash flow development continued positive, progress with new business models

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Analytikerkommentar2024-10-16 06:22 av

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight will publish its Q3 results on Friday, October 18 at 1:00 pm EEST. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Pressmeddelande2024-10-14 10:00

Modulight to publish its interim report for January–September 2024 on October 18, 2024

Regulatoriskt pressmeddelande2024-09-16 10:20

Modulight Corporation: Managers' Transactions – Jari Sillanpää

Regulatoriskt pressmeddelande2024-09-16 10:20

Modulight Corporation: Managers' Transactions – Virpi Sillanpää

Regulatoriskt pressmeddelande2024-09-11 10:00

Modulight Corporation: Managers' Transactions – Jari Hopsu

Regulatoriskt pressmeddelande2024-09-11 10:00

Modulight Corporation: Managers' Transactions – Ulla Haapanen

Regulatoriskt pressmeddelande2024-08-22 12:30

Modulight Corporation: Managers' Transactions – Lasse Orsila

Aktieanalys2024-08-19 08:51 av

Modulight Q2'24: Top line needs a boost

Modulight's Q2 revenue declined year-on-year and missed our forecasts. However, operating loss was lower than expected. The company had expanded its project pipeline to 30 and continued to roll out its pay-per-treatment (PPT) pricing model during the period. The model is not generating significant revenue at this time.

Regulatoriskt pressmeddelande2024-08-16 10:02

Modulight: Implementation of the new business model progressed and cash flow improved

Forum uppdateringar

Cheers, We’ve recently released an Initiation of Coverage Report on Modulight. Modulight is a laser company focused on biomedical, medical, and life science applications. The company grew profitably during the previous decade and is now looking to get back on that track after some...

2023-05-22 12:05

by Antti Siltanen

6

Modulights Q3-resultat var lägre än förväntat när det gäller omsättningen, även om vinsten och kassaflödet var i linje med prognoserna. Omsättningen påverkades negativt av övergången till PPT-modellen och förseningar i prototypleveranser. Utsikterna för 2024 verkar vara under målen...

2024-10-20 14:07

by börsen84

1

Modulights Q3-resultat under förväntningarna – intäkterna påverkades av förändringar i intäktsmodellen och leveransförseningar Modulight offentliggjorde på fredagen sitt resultat för tredje kvartalet, där intäkterna var klart lägre än förväntat. Bolagets vinst och kassaflöde motsvarade...

2024-10-18 23:09

by börsen84

1

Here is a high-quality and free analysis of Modylight. Inderes Modulight: 2023 landed below targets - Inderes Modulight said its revenue for 2023 will be around 4 MEUR and its EBIT will deteriorate year-on-year. The guidance marks the third consecutive year of business contraction...

2024-01-02 22:02

by börsen84

1

Here is a really good analysis. “The Q2 report was disappointing compared to our expectations and the market reaction was also strongly negative. The company’s revenue of EUR 1.1 million was modest, especially when considering the large contract that still supported the figures in...

2023-08-21 20:37

by börsen84

1

Modulight: Positiv utveckling fortsatte, uppstarten av verksamhet på lokal nivå i USA framskred väl. Modulight Corporation Modulight, Inc.

2023-08-19 08:41

by börsen84

1

Here’s a new analysis of Modylight for you. Inderes — Connecting Investors and Companies Modulight: Checking estimates ahead of the Q2 report Our Q2 estimates have expected strong growth from the company, based on the start of commercialization of the ophthalmic laser during Q2'23...

2023-08-11 08:19

by börsen84

1

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.